alphaa-synuclein in human and transgenic mouse brain. J Neurosci 20: 6365–6373. 12. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840. 13. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, et al. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease. Neurology 53: 1858–1860. 14. Satoh J, Kuroda Y (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson’s disease in a Japanese population. J Neurol Sci 189: 113–117. 15. Hutter CM, Samii A, Factor SA, Nutt JG, Higgins DS, et al. (2008) Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease. Eur J Neurol 15: 134–139. 16. Healy DG, Abou-Sleiman PM, Casas JP, Ahmadi KR, Lynch T, et al. (2006) UCHL-1 is not a Parkinson’s disease susceptibility gene. Ann Neurol 59: 627–633. 17. Cartier AE, Djakovic SN, Salehi A, Wilson SM, Masliah E, et al. (2009) Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J Neurosci 29: 7857–7868. 18. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, et al. (2002) Chemistry-based functional proteomics reveals novel members of the deubiqui- tinating enzyme family. Chem Biol 9: 1149–1159. 19. Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, et al. (2005) Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res 80: 247–259. 20. Tiscornia G, Singer O, Ikawa M, Verma IM (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proceedings of the National Academy of Sciences of the United States of America 100: 1844–1848. 21. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, et al. (2002) Differential neuropathological alterations in transgenic mice expressing alpha- synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68: 568–578. 22. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, et al. (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126: 775–788. 23. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, et al. (2002) Chemistry-based functional proteomics reveals novel members of the deubiqui- tinating enzyme family. Chemistry & biology 9: 1149–1159. 24. Roeder LM, Poduslo SE, Tildon JT (1982) Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res 8: 671–682. 25. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482–497. 26. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214–3220. 27. Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, et al. (2005) Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell Neurosci 28: 326–334. 28. Liu Y, Lashuel HA, Choi S, Xing X, Case A, et al. (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 10: 837–846. 29. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, et al. (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurode- generation. J Neurosci 30: 8083–8095. 30. McLean PJ, Kawamata H, Hyman BT (2001) Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104: 901–912. 31. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K (2008) Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 283: 23731–23738. 32. Kabuta T, Wada K (2008) Insights into links between familial and sporadic Parkinson’s disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy 4: 827–829. 33. Tanida I, Ueno T, Kominami E (2004) Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 279: 47704–47710. 34. Tanida I, Ueno T, Kominami E (2004) LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 36: 2503–2518. 35. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, et al. (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24: 8055–8068. Differential Effects of UCH-L1 Inhibition on a-Syn 36. Wooten MW, Hu X, Babu JR, Seibenhener ML, Geetha T, et al. (2006) Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62’s role in neurodegenerative disease. J Biomed Biotechnol 2006: 62079. 37. Seibenhener ML, Geetha T, Wooten MW (2007) Sequestosome 1/p62–more than just a scaffold. FEBS Lett 581: 175–179. 38. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, et al. (2007) p62/ SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282: 24131–24145. 39. Ichimura Y, Kominami E, Tanaka K, Komatsu M (2008) Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy 4: 1063–1066. 40. Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson’s disease. Curr Opin Neurol 21: 676–682. 41. McKeith IG, Mosimann UP (2004) Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 10 Suppl 1: S15–18. 42. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha- synuclein locus triplication causes Parkinson’s disease. Science 302: 841. 43. Cookson MR, van der Brug M (2008) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209: 5–11. 44. Wang YL, Takeda A, Osaka H, Hara Y, Furuta A, et al. (2004) Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1- deficient gad mouse. Brain research 1019: 1–9. 45. Lee SH, Choi JH, Lee N, Lee HR, Kim JI, et al. (2008) Synaptic protein degradation underlies destabilization of retrieved fear memory. Science 319: 1253–1256. 46. Ehlers MD (2003) Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 6: 231–242. 47. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, et al. (2003) Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 40: 595–607. 48. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, et al. (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274: 33855–33858. 49. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) Alpha- synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278: 25009–25013. 50. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585–595. 51. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, et al. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron micros- copy study. J Neuropathol Exp Neurol 64: 113–122. 52. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, et al. (2007) Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat Chem Biol 3: 331–338. 53. Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131: 1969–1978. 54. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292–1295. 55. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, et al. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci 29: 13578–13588. 56. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L (2009) Abberant alpha- synuclein confers toxicity to neurons in part through inhibition of chaperone- mediated autophagy. PLoS One 4: e5515. 57. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC, Jr., et al. (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease. Brain Res 956: 156–165. 58. Rideout HJ, Lang-Rollin I, Stefanis L (2004) Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol 36: 2551–2562. 59. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, et al. (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy- deficient mice. Cell 131: 1149–1163. 60. Wang QJ, Ding Y, Kohtz DS, Mizushima N, Cristea IM, et al. (2006) Induction of autophagy in axonal dystrophy and degeneration. J Neurosci 26: 8057–8068. 61. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K (2008) Aberrant interaction between Parkinson’s disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem. 62. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, et al. (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson’s disease. Proc Natl Acad Sci U S A 106: 4635–4640. PLoS ONE | www.plosone.org 14 April 2012 | Volume 7 | Issue 4 | e34713